目的：分析顺尔宁联合布地奈德治疗小儿哮喘的效果及对外周血嗜酸性粒细胞的影响。方法以我院2012年8月～2014年3月收治的80例哮喘患儿为研究对象，随机将其分为两组，各40例，对照组患儿给予布地奈德治疗，实验组在对照组基础上联合顺尔宁治疗，比较两组临床疗效、治疗前后肺功能指标（FEV1、FVC）及外周血嗜酸性粒细胞(Eos)水平。结果实验组治疗显效率为92.5%，与对照组的80.0%比较差异有统计学意义（P＜0.05）。另外，两组治疗后FEV1[（1.95±0.47）VS（1.52±0.35）]L、FVC[（2.48±0.94）VS（2.06±0.90）]L及Eos[（0.27±0.06）VS（0.40±0.12）]×109比较差异有统计学意义（P＜0.05）。结论顺尔宁联合布地奈德治疗小儿哮喘疗效显著，能明显改善患儿肺功能，降低Eos水平，值得临床推广。%Objective To study the effect of Montelukast Combined with budesonide in treatment of pediatric asthma and the effect of peripheral blood eosinophil. Methods 80 cases of children with asthma were treated in our hospital from August 2012 to March 2014 as the research object, were randomly divided into two groups, each of 40 cases, the control group were given budesonide treatment, the experimental group combined montelukast therapy based on control group, compared pulmonary function index (FEV1, FVC) and peripheral blood eosinophil (Eos) level between two groups before and after. Results The markedly effective rate of experimental group was 92.5%, was significant difference among control group of 80%(P<0.05). In addition, the two groups after treatment of FEV1[(1.95±0.47) VS (1.52±0.35)]L, FVC[(2.48± 0.94) VS (2.06±0.90)]L and Eos[(0.27±0.06) VS (0.40±0.12)] x 109, difference was statistically significant (P<0.05). Conclusion The curative effect of Montelukast combined with budesonide in treating asthma children is significant, can significantly improve the pulmonary function and decrease the level of Eos, is worth the clinical promotion.
展开▼
